CN108276405A - A kind of synthesis technology of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester - Google Patents

A kind of synthesis technology of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester Download PDF

Info

Publication number
CN108276405A
CN108276405A CN201810201551.2A CN201810201551A CN108276405A CN 108276405 A CN108276405 A CN 108276405A CN 201810201551 A CN201810201551 A CN 201810201551A CN 108276405 A CN108276405 A CN 108276405A
Authority
CN
China
Prior art keywords
pyridine
added
ethyl ester
carboxylic acids
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201810201551.2A
Other languages
Chinese (zh)
Inventor
王玉环
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanan Chuangpei Electronic Technology Co Ltd
Original Assignee
Nanan Chuangpei Electronic Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanan Chuangpei Electronic Technology Co Ltd filed Critical Nanan Chuangpei Electronic Technology Co Ltd
Priority to CN201810201551.2A priority Critical patent/CN108276405A/en
Publication of CN108276405A publication Critical patent/CN108276405A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

The invention belongs to medicine intermediate fields, and in particular to a kind of synthesis technology of 2 carboxylic acid, ethyl ester of medicine intermediate imidazo [1,2 A] pyridine.The present invention can react after first mixing (2 oxo 1 (2H) pyridyl group) acetonitrile and Ethyl formate at low temperature, it is added in ethyl alcohol after reacting the reactants separate generated, and potassium carbonate is added, carry out back flow reaction, target product is obtained after reaction, easy to operate, mild condition of the invention, high income, purifying is convenient, product quality is excellent, and safety is good, reduces pollution.

Description

A kind of synthesis technology of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester
Technical field
The invention belongs to medicine intermediate fields, and in particular to a kind of medicine intermediate imidazo [1,2-A] pyridine -2- carboxylics The synthesis technology of acetoacetic ester.
Background technology
Minodronic acid 2 (1- hydroxyls -2- (imidazo [1,2-a] pyridin-3-yl) ethane -1,1- two banks) is a kind for the treatment of The hypercalcinemia caused by osteoporosis and malignant tumour belongs to third generation bisphosphonates.It is by Japanese Yamanouchi public affairs The new type heterocycle double phosphinic acid compounds of exploitation are taken charge of, which is incadonate sodium, sodium alendronate respectively With 2 times, 10 times and 100 times of Pamidronate Disodium.Due to the excellent curative effect of the product and smaller stomach side effect, make it have Extensive potential applicability in clinical practice.
Imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester is the key intermediate for preparing minodronic acid, and therefore, exploitation is a kind of Raw material is cheap and easy to get, easy to operate, and reaction condition is mild, and production cost is low, and yield is high, is suitble to large-scale production, storage, production The method of process safety is completely necessary.
Invention content
The technical problems to be solved by the invention:For imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester synthesis technology it is multiple It is miscellaneous, it is cumbersome, the problem of low yield, provide a kind of conjunction of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester At technique.
In order to solve the above technical problems, the technical solution adopted by the present invention is:
Synthetic route of the present invention is as follows:
Specific synthesis step is as follows:
(1) in molar ratio 1:5, (2- oxos -1 (2H)-pyridyl group) acetonitrile and Ethyl formate are weighed, three-necked flask is added In, it is put into ice-water bath, controlled at 5~10 DEG C, and sodium ethoxide is added, be stirred to react 6~8h, to three-necked flask after reaction Middle addition distilled water, stands overnight, and collects oil phase;
(2) in mass ratio 1:8, oil phase and ethyl alcohol mixing are weighed, potassium carbonate is added after mixing, is heated to flowing back, reflux is anti- 30~40min is answered, it is 4.5~5.0 that vinegar acid for adjusting pH value is used after reaction, and rotary evaporated to dryness after adjusting is collected solid, is washed with water It is dry after washing, you can to obtain imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester.
The molar ratio of the sodium ethoxide and (2- oxos -1 (2H)-pyridyl group) acetonitrile is 5~7:1.
The potassium carbonate addition is the 10~20% of oil phase quality.
Compared with other methods, advantageous effects are the present invention:
(1) present invention can be into after first mixing (2- oxos -1 (2H)-pyridyl group) acetonitrile and Ethyl formate at low temperature Row reaction, and synthetic method, without using catalyst, wherein Ethyl formate is liquid charging stock, be added before reacting it is excessive, then without Other organic solvent need to be added, the processes such as separation, the recycling of organic solvent need not be carried out, simple for process, wherein sodium ethoxide can Reaction response is promoted to carry out completely;
(2) reactant of (2- oxos -1 (2H)-pyridyl group) acetonitrile and Ethyl formate is added in ethyl alcohol, and carbonic acid is added Potassium carries out back flow reaction, target product is obtained after reaction, easy to operate, mild condition of the invention, high income, purifying is convenient, production Quality is excellent, and safety is good, reduces pollution.
Description of the drawings
Fig. 1 is the hydrogen nuclear magnetic resonance spectrogram of imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester.
Fig. 2 is the carbon-13 nmr spectra figure of imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester.
Specific implementation mode
In molar ratio 1:5, (2- oxos -1 (2H)-pyridyl group) acetonitrile and Ethyl formate are weighed, is added in three-necked flask, puts Enter in ice-water bath, controlled at 5~10 DEG C, and sodium ethoxide is added, sodium ethoxide and (2- oxos -1 (2H)-pyridyl group) acetonitrile Molar ratio is 5~7:1, it is stirred to react 6~8h, distilled water is added after reaction into three-necked flask, is stood overnight, oil phase is collected; In mass ratio 1:8, oil phase and ethyl alcohol mixing are weighed, 10~20% potassium carbonate of oil phase quality are added after mixing, are heated to flowing back, 30~40min of back flow reaction, it is 4.5~5.0 that vinegar acid for adjusting pH value is used after reaction, and rotary evaporated to dryness after adjusting collects solid, It is dry after being washed with water, you can to obtain imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester.
Example 1
In molar ratio 1:5, (2- oxos -1 (2H)-pyridyl group) acetonitrile and Ethyl formate are weighed, is added in three-necked flask, puts Enter in ice-water bath, controlled at 5 DEG C, and sodium ethoxide is added, mole of sodium ethoxide and (2- oxos -1 (2H)-pyridyl group) acetonitrile Than being 5:1, it is stirred to react 6h, distilled water is added after reaction into three-necked flask, is stood overnight, oil phase is collected;In mass ratio 1: 8, oil phase and ethyl alcohol mixing are weighed, 10% potassium carbonate of oil phase quality is added after mixing, is heated to flowing back, back flow reaction 30min, It is 4.5 that vinegar acid for adjusting pH value is used after reaction, and rotary evaporated to dryness after adjusting collects solid, dry after being washed with water, you can to obtain Imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester, purity 99.3%, yield 87%.
Example 2
In molar ratio 1:5, (2- oxos -1 (2H)-pyridyl group) acetonitrile and Ethyl formate are weighed, is added in three-necked flask, puts Enter in ice-water bath, controlled at 7 DEG C, and sodium ethoxide is added, mole of sodium ethoxide and (2- oxos -1 (2H)-pyridyl group) acetonitrile Than being 6:1, it is stirred to react 7h, distilled water is added after reaction into three-necked flask, is stood overnight, oil phase is collected;In mass ratio 1: 8, oil phase and ethyl alcohol mixing are weighed, 15% potassium carbonate of oil phase quality is added after mixing, is heated to flowing back, back flow reaction 35min, It is 4.7 that vinegar acid for adjusting pH value is used after reaction, and rotary evaporated to dryness after adjusting collects solid, dry after being washed with water, you can to obtain Imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester, purity 99.5%, yield 89%.
Example 3
In molar ratio 1:5, (2- oxos -1 (2H)-pyridyl group) acetonitrile and Ethyl formate are weighed, is added in three-necked flask, puts Enter in ice-water bath, controlled at 10 DEG C, and sodium ethoxide is added, sodium ethoxide rubs with (2- oxos -1 (2H)-pyridyl group) acetonitrile You are than being 7:1, it is stirred to react 8h, distilled water is added after reaction into three-necked flask, is stood overnight, oil phase is collected;In mass ratio 1:8, oil phase and ethyl alcohol mixing are weighed, 20% potassium carbonate of oil phase quality is added after mixing, is heated to flowing back, back flow reaction 40min, it is 5.0 that vinegar acid for adjusting pH value is used after reaction, and rotary evaporated to dryness after adjusting collects solid, dry after being washed with water, i.e., Imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester, purity 99.6%, yield 89% can be obtained.

Claims (3)

1. a kind of synthesis technology of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester, it is characterised in that specific synthesis Step is:
(1) in molar ratio 1:5, (2- oxos -1 (2H)-pyridyl group) acetonitrile and Ethyl formate are weighed, is added in three-necked flask, puts Enter in ice-water bath, controlled at 5~10 DEG C, and sodium ethoxide is added, be stirred to react 6~8h, adds into three-necked flask after reaction Enter distilled water, stand overnight, collects oil phase;
(2) in mass ratio 1:8, oil phase and ethyl alcohol mixing are weighed, potassium carbonate is added after mixing, is heated to flowing back, back flow reaction 30 ~40min, it is 4.5~5.0 that vinegar acid for adjusting pH value is used after reaction, and rotary evaporated to dryness after adjusting collects solid, after being washed with water It is dry, you can to obtain imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester.
2. a kind of synthesis work of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester according to claim 1 Skill, it is characterised in that:The molar ratio of the sodium ethoxide and (2- oxos -1 (2H)-pyridyl group) acetonitrile is 5~7:1.
3. a kind of synthesis work of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester according to claim 1 Skill, it is characterised in that:The potassium carbonate addition is the 10~20% of oil phase quality.
CN201810201551.2A 2018-03-12 2018-03-12 A kind of synthesis technology of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester Withdrawn CN108276405A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810201551.2A CN108276405A (en) 2018-03-12 2018-03-12 A kind of synthesis technology of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810201551.2A CN108276405A (en) 2018-03-12 2018-03-12 A kind of synthesis technology of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester

Publications (1)

Publication Number Publication Date
CN108276405A true CN108276405A (en) 2018-07-13

Family

ID=62809465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810201551.2A Withdrawn CN108276405A (en) 2018-03-12 2018-03-12 A kind of synthesis technology of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester

Country Status (1)

Country Link
CN (1) CN108276405A (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1045782A (en) * 1989-02-17 1990-10-03 武田药品工业株式会社 The preparation of imidazopyridine and application thereof
WO1998058905A1 (en) * 1997-06-25 1998-12-30 Yamanouchi Pharmaceutical Co., Ltd. Novel amidrazone derivatives having antifungal activity
CN102101860A (en) * 2010-12-23 2011-06-22 北京满格医药科技有限公司 Novel method for synthesizing key intermediate of minodronate
CN104135859A (en) * 2011-12-28 2014-11-05 全球血液疗法公司 Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
CN104271561A (en) * 2012-03-06 2015-01-07 佐蒂斯有限责任公司 Phenicol antibacterials
CN107778313A (en) * 2016-08-29 2018-03-09 鲁南制药集团股份有限公司 A kind of process for purification of the acetic acid of Minodronate intermediate imidazo [1,2 a] pyridine 3

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1045782A (en) * 1989-02-17 1990-10-03 武田药品工业株式会社 The preparation of imidazopyridine and application thereof
WO1998058905A1 (en) * 1997-06-25 1998-12-30 Yamanouchi Pharmaceutical Co., Ltd. Novel amidrazone derivatives having antifungal activity
CN102101860A (en) * 2010-12-23 2011-06-22 北京满格医药科技有限公司 Novel method for synthesizing key intermediate of minodronate
CN104135859A (en) * 2011-12-28 2014-11-05 全球血液疗法公司 Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
CN104271561A (en) * 2012-03-06 2015-01-07 佐蒂斯有限责任公司 Phenicol antibacterials
CN107778313A (en) * 2016-08-29 2018-03-09 鲁南制药集团股份有限公司 A kind of process for purification of the acetic acid of Minodronate intermediate imidazo [1,2 a] pyridine 3

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CRISTINA M. AL MATARNEH等: "Reactions of ethyl cyanoformate with cycloimmonium salts: a direct pathway to fused or substituted azaheterocycles", 《TETRAHEDRON》 *
JEAN-LUC MOUTOU等: "A Two-Steps Benzotriazole-Assisted Synthesis of 3-Amino-2-Ethoxycarbonyl Imidazo [1,2-a] Pyridines and Related Compounds.", 《TETRAHEDRON LETTERS》 *
JOSEPH G. LOMBARDINO等: "Preparation and New Reactions of Imidazo[l,2-o]pyridines", 《J.AM.CHEM.SOC.》 *
刘建超等: "《含氮稠杂环衍生物的合成及其生物活性》", 30 September 2009, 华中师范大学出版社 *

Similar Documents

Publication Publication Date Title
Ding et al. Highly efficient and practical optical resolution of 2‐amino‐2′‐hydroxy‐1, 1′‐binaphthyl by molecular complexation with N‐benzylcinchonidium chloride: a direct transformation to binaphthyl amino phosphine
CN108017583B (en) Preparation method of kebomei
CN111018767B (en) Preparation method of D-proline derivative and intermediate thereof
CN104945384A (en) Preparation method of 5-chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4(1H,3H)-pyrimidine dione or salts thereof
CN108467360A (en) A kind of Ah pa replaces the Preparation Method And Their Intermediate of Buddhist nun
BR112015030527B1 (en) ACID ESTER COMPOUNDS 3- (5-REPLACED OXY-2,4-DINITROPHENYL) -2-OXO-PROPYLIC, PROCESS AND APPLICATIONS OF THE SAME
CN103214521B (en) Method for preparing dibenzophosphole derivants
CN107501112A (en) A kind of Chiral Synthesis of chiral beta amino acids and the synthetic method of medicine intermediate
CN112062712A (en) Preparation method of 2- (5-bromo-3-methylpyridin-2-yl) acetic acid hydrochloride
CN106366036B (en) Bis- [(2- amino-ethyl) amino] benzo [g] isoquinolin -5,10- diketone 2-maleates of 6,9- and its synthesis technology
CN101531654B (en) Preparation method for Rupatadine
CN109867673A (en) A method of synthesis Pabuk former times benefit cloth
CN108276405A (en) A kind of synthesis technology of medicine intermediate imidazo [1,2-A] pyridine-2-carboxylic acids ethyl ester
CN102199120B (en) Method for synthesizing 2,2'-bipyridine-4,4'-dicarboxylic acid
Sifniades et al. Synthesis of L-lysine. Simultaneous resolution/racemization of. alpha.-amino-. epsilon.-caprolactam
CN104072369B (en) A kind of technique preparing Diisopropyl malonate
CN113603636A (en) Preparation method of Sotoraib intermediate
CN111518032A (en) Preparation method of Gboxin
CN110770231B (en) Preparation method of tyrosine kinase inhibitor and intermediate thereof
Liu et al. Syntheses, Characterizations, and Reactivity of Two Cu (I)-Amido Complexes: Proposed Intermediate in Cu (I)-Catalyzed Goldberg Reaction
CN108727360A (en) A kind of preparation method of 2- pyrrole radicals -1,3- morpholine class compounds
Sarkar et al. Lithium hydride as an efficient reagent for the preparation of 1, 2-anhydro inositols: Does the reaction proceed through ‘axial rich’conformation?
CN113956139B (en) Green method for converting thiazolidine derivative into carbonyl compound
CN108033937A (en) One kettle way prepares the method that lactone founds in biphenyl -4- formyls section
CN103058998B (en) The preparation technology of a kind of AMD3465

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20180713

WW01 Invention patent application withdrawn after publication